- Home
- SABS vs TENX Comparison
SABS vs TENX Comparison
Compare SABS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- TENX
- Stock Information
- Founded
- SABS 2014
- TENX 1967
- Country
- SABS United States
- TENX United States
- Employees
- SABS N/A
- TENX N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- SABS Health Care
- TENX Health Care
- Exchange
- SABS Nasdaq
- TENX Nasdaq
- Market Cap
- SABS 19.0M
- TENX 21.7M
- IPO Year
- SABS N/A
- TENX N/A
- Fundamental
- Price
- SABS $1.20
- TENX $6.42
- Analyst Decision
- SABS Strong Buy
- TENX Strong Buy
- Analyst Count
- SABS 5
- TENX 3
- Target Price
- SABS $12.40
- TENX $16.00
- AVG Volume (30 Days)
- SABS 36.5K
- TENX 43.8K
- Earning Date
- SABS 05-19-2025
- TENX 03-25-2025
- Dividend Yield
- SABS N/A
- TENX N/A
- EPS Growth
- SABS N/A
- TENX N/A
- EPS
- SABS N/A
- TENX N/A
- Revenue
- SABS $1,512,723.00
- TENX N/A
- Revenue This Year
- SABS N/A
- TENX N/A
- Revenue Next Year
- SABS N/A
- TENX N/A
- P/E Ratio
- SABS N/A
- TENX N/A
- Revenue Growth
- SABS N/A
- TENX N/A
- 52 Week Low
- SABS $1.36
- TENX $2.77
- 52 Week High
- SABS $5.01
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- SABS 33.63
- TENX 49.83
- Support Level
- SABS $1.53
- TENX $6.00
- Resistance Level
- SABS $1.80
- TENX $6.76
- Average True Range (ATR)
- SABS 0.15
- TENX 0.42
- MACD
- SABS 0.02
- TENX 0.01
- Stochastic Oscillator
- SABS 0.00
- TENX 40.37
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.